Jelle Dylus

MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance

Jordy C.G. van der Zwet, Jessica G. C. A. M. Buijs-Gladdines, Valentina Cordo’ et al. · Leukemia · 2021 · 46 citations · Full text

Hematological Malignancy, Central Pathway, Mixed-phenotype Acute Leukemia +10

Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines

Marion A.A. Libouban, Jeroen A.D.M. de Roos, Joost C.M. Uitdehaag et al. · Oncotarget · 2017 · 37 citations · Full text

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017

Joost C.M. Uitdehaag, Jeffrey J. Kooijman, Jeroen A.D.M. de Roos et al. · Molecular Cancer Therapeutics · 2018 · 27 citations

Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020

Jeffrey J. Kooijman, Wilhelmina E. van Riel, Jelle Dylus et al. · Frontiers in Oncology · 2022 · 20 citations · Full text

Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors

Joost C.M. Uitdehaag, Jeroen A.D.M. de Roos, Martine B.W. Prinsen et al. · Molecular Cancer Therapeutics · 2016 · 18 citations